PUNE, India, November 4, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape" to its store, stating that although the market has recently been hit by the patent expirations of a number of the leading gastrointestinal products, such as Nexium and Remicade, the approval of new drugs, as well as rising prevalence, are expected to drive considerable growth.
The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022, representing a compound annual growth rate of 4.45%. Complete report on Gastrointestinal Drug Market with 23 market data tables and 71 figures, spread across 161 pages is available at http://www.rnrmarketresearch.com/global-gastrointestinal-drug-market-to-2022-pipeline-characterized-by-emerging-biologic-therapies-while-tnf-inhibitors-and-ppis-continue-to-dominate-therapy-landscape-market-report.html .
Disease and disorders involving the gastrointestinal system are among the most common conditions encountered worldwide, and many of them can have a significant impact on quality of life. The direct and indirect socio-economic burden associated with gastrointestinal disorders is profound. The direct costs of medical consultations and treatments in the US for gastroesophageal reflux disease alone are estimated to amount to $9.3 billion, while the indirect costs due to absenteeism and impairment in work performance total $75 billion (Chait, 2010).
Despite the significant global socio-economic burden, many gastrointestinal disorders are still poorly understood, and there is a significant unmet need for novel, safe and effective therapies, as treatment options are often lacking, causing many patients to be dissatisfied with their treatment. The unmet need and demand for better treatments and the high prevalence of digestive conditions make the gastrointestinal market an attractive candidate for therapeutic development.
Companies Analysis and Positioning discussed in this research are AbbVie, Takeda, Johnson & Johnson, AstraZeneca, Alexion, Allergan and Celgene.
This report covers all gastrointestinal disorders, but there is a particular focus on three key diseases: gastroesophageal reflux disease, irritable bowel syndrome and inflammatory bowel disease. The global gastrointestinal market was valued at $35.7 billion in 2015 and is projected to grow at a compound annual growth rate (CAGR) of 4.45%, reaching $48.4 billion in 2022. Proton pump inhibitors (PPIs) and tumor necrosis factor (TNF)-α inhibitors generate the largest revenues and continue to retain commercial prominence. Key drivers of market growth will be the uptake of recently approved premium products, rising prevalence, and promising late-stage products, including a number of biologic therapies that are expected to be highly valuable.
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=738170 .
Scope of this report: The gastrointestinal market landscape is expected to change substantially with the advent of promising novel pipeline products. There are 937 gastrointestinal pipeline products in active development, of which small molecules and biologics account for 53% and 38%, respectively. Which molecular targets are most prominent within the pipeline. How do the key indications differ in terms of molecule type. How does the composition of the pipeline compare with that of the existing market. What mechanisms of action are most common for pipeline drug. Which products will be the biggest drivers for market growth. Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the gastrointestinal market set to change and What CAGR will these companies register in the forecast period.
Another newly published market research report titled on Gastric Ulcers - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Gastric Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Ache Laboratorios Farmaceuticos S/A, Astellas Pharma Inc., ChoDang Pharm Co., Ltd., Kukje Pharmaceutical Industry Co., Ltd. and XuanZhu Pharma Co., Ltd. Gastric Ulcers Pipeline market research report of 43 pages is available at http://www.rnrmarketresearch.com/gastric-ulcers-pipeline-review-h2-2016-market-report.html .
Explore more reports on Gastrointestinal therapeutics
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.
2nd floor, Metropole,
Next to Inox theatre, Bund garden road,
+ 1 888 391 5441
SOURCE RnR Market Research